Home › NDC Lookup › RxCUI directory › RxCUI 2719494

2.5 ML linvoseltamab-gcpt 2 MG/ML Injection — RxCUI 2719494

RxNorm drug concept · Semantic clinical drug
RxCUI 2719494 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2719494
Official name2.5 ML linvoseltamab-gcpt 2 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aslinvoseltamab-gcpt 5 MG per 2.5 ML Injection; linvoseltamab-gcpt 5 MG in 2.5 ML Injection
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How 2.5 ML linvoseltamab-gcpt 2 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 2.5 ML linvoseltamab-gcpt 2 MG/ML Injection RxCUI 2719494

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Linvoseltamab 2719416
    • Linvoseltamab-gcpt 2719477
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Lynozyfic 2719485
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Linvoseltamab Injection 2719480
    • Linvoseltamab-gcpt Injection 2719482
    • Linvoseltamab Injectable Product 2719479
    • Linvoseltamab-gcpt Injectable Product 2719481
    • Linvoseltamab Injection [Lynozyfic] 2719488
    • Linvoseltamab-gcpt Injection [Lynozyfic] 2719489
    • Lynozyfic Injectable Product 2719487
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Linvoseltamab-gcpt 2 MG/ML SCDC · 2719493
  • Linvoseltamab Injection SCDF · 2719480
  • Linvoseltamab-gcpt Injection SCDFP · 2719482
  • Linvoseltamab Injectable Product SCDG · 2719479
  • Linvoseltamab-gcpt Injectable Product SCDGP · 2719481

Brand-Name Concepts

  • 2.5 ML linvoseltamab-gcpt 2 MG/ML Injection [Lynozyfic] SBD · 2719497
  • Linvoseltamab-gcpt 2 MG/ML [Lynozyfic] SBDC · 2719496
  • Linvoseltamab Injection [Lynozyfic] SBDF · 2719488
  • Linvoseltamab-gcpt Injection [Lynozyfic] SBDFP · 2719489
  • Lynozyfic Injectable Product SBDG · 2719487
  • Lynozyfic BN · 2719485

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2719494 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
61755-0054-01 1 VIAL, SINGLE-DOSE in 1 CARTON (61755-054-01) / 2.5 mL in... LYNOZYFIC Regeneron Pharmaceuticals, Inc. 2025-07-02
61755-0056-01 1 VIAL, SINGLE-DOSE in 1 CARTON (61755-056-01) / 10 mL in 1... LYNOZYFIC Regeneron Pharmaceuticals, Inc. 2025-07-02
Observed labelers: Regeneron Pharmaceuticals, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9601 Inj linvoseltamab-gcpt 1 mg 2 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.